The developing countries India and China represent growing markets for active pharmaceutical ingredients (APIs) from western regulated markets. This is the conclusion of Ms Kate Kuhrt, Director of Generics and API Intelligence at Thomson Reuters. “With the pharmaceutical markets in India and China expected to continue to grow at double-digit rates, while traditional pharmaceutical markets, such as the US, Japan and Western Europe remain stagnant, it is no surprise that many API manufacturers have set their eyes on India and China”, she states.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- Canada approves pegfilgrastim biosimilar Pexegra
- Insulin aspart and denosumab biosimilars approved in US
- FDA approves tocilizumab biosimilar Avtozma
- January 2025 biosimilar approvals in Europe
- MORE EDITORIAL SECTIONS
- Search
Post your comment